OraSure Technologies, Inc. (OSUR)
| Market Cap | 423.35M |
| Revenue (ttm) | 387.48M |
| Net Income (ttm) | -17.93M |
| Shares Out | 73.24M |
| EPS (ttm) | -0.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 607,655 |
| Open | 5.69 |
| Previous Close | 5.75 |
| Day's Range | 5.49 - 5.84 |
| 52-Week Range | 2.62 - 7.26 |
| Beta | 0.09 |
| Analysts | Buy |
| Price Target | 5.99 (+3.63%) |
| Earnings Date | May 9, 2023 |
About OSUR
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebol... [Read more]
Financial Performance
In 2022, OSUR's revenue was $387.48 million, an increase of 65.82% compared to the previous year's $233.67 million. Losses were -$17.93 million, -22.02% less than in 2021.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for OSUR stock is "Buy." The 12-month stock price forecast is $5.99, which is an increase of 3.63% from the latest price.
News
3 Low-Beta Stocks to Buy to Combat the Volatile Market
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. OraSure Technologies (OSUR), Compa?
Surging Earnings Estimates Signal Upside for OraSure (OSUR) Stock
OraSure (OSUR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
OraSure Technologies (OSUR) Surpasses Q4 Earnings and Revenue Estimates
OraSure (OSUR) delivered earnings and revenue surprises of 2,000% and 26.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability
InteliSwab ® revenue of $88.9 million in Q4, up 12% sequentially; wins two new federal government contracts extending the tail on InteliSwab ® revenue
2022 Fourth Quarter Earnings Conference Call Tuesday, February 14, 2023, 5:00 p.m. ET
BETHLEHEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth quarter financial results and certai...
OraSure Technologies Continues its Dedication to Ending the HIV Epidemic
Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS Day Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS Day
OraSure Technologies to Present at Stephens Annual Investment Conference
BETHLEHEM, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytic...
OraSure Technologies (OSUR) Q3 Earnings and Revenues Top Estimates
OraSure (OSUR) delivered earnings and revenue surprises of 216.67% and 26.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year
InteliSwab® revenue of $79.6 million in Q3, up 85% sequentially; Company continues to expand test production capacity
OraSure Technologies Receives General Clearance for its ORAcollect®•Dx Device for Over-the Counter (OTC) Use from the U.S. Food and Drug Administration (FDA)
FDA Clearance Received Through Partnership with Grifols to Support Screening for Risk of Alpha1- Antripsyn Deficiency (Alpha-1) in U.S. Adult Population
InteliSwab® COVID-19 Rapid Test Now Available in Amazon's Online Store
BETHLEHEM, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced ...
2022 Third Quarter Earnings Conference Call Tuesday, November 8, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., Nov. 01, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 third quarter financial results and certain...
3 Penny Stocks That Are Too Cheap to Ignore
The traditional definition of penny stocks is those companies whose shares trade for $5 or less. It's never easy finding cheap penny stocks to buy amongst this oppressed group because they are often s...
OraSure Technologies Receives $8.6 Million BARDA Contract to Develop 2nd Generation Ebola Test
BETHLEHEM, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced...
OraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention
The effort promotes HIV testing and awareness in populations disproportionately affected by HIV The effort promotes HIV testing and awareness in populations disproportionately affected by HIV
OraSure Partners with Mars Petcare in One of the Largest Ever Microbiome Studies to Evaluate Pet Health
BETHLEHEM, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced...
OraSure Technologies (OSUR) Reports Break-Even Earnings for Q2
OraSure (OSUR) delivered earnings and revenue surprises of 100% and 13.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year
InteliSwab ® revenue of $43.1 million in Q2, up 95% sequentially with significant scaling in production
OraSure Technologies to Hold 2022 Second Quarter Earnings Conference Call Tuesday, August 9, 2022, 5:00 p.m. ET
BETHLEHEM, Pa., Aug. 02, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 second quarter financial results and certai...
OraSure's Ongoing Commitment to End the Hepatitis C Epidemic Heats Up at the Racetrack
Race to End Hep C initiative demonstrates the ability of easy-to-administer, low-cost testing solutions to identify patients and direct them to appropriate care Race to End Hep C initiative demonstrat...
OraSure Technologies Launches New Product for Microbiome Researchers to Study DNA and RNA
BETHLEHEM, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced ...
OraSure Technologies Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BETHLEHEM, Pa., June 08, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced ...
InteliSwab® COVID-19 Rapid Test Selected by Federal Government for Nationwide School Testing
The rapid at-home COVID-19 test is authorized for ages 2 and up The rapid at-home COVID-19 test is authorized for ages 2 and up
Carrie Eglinton Manner Appointed Chief Executive Officer of OraSure
Company Concludes Strategic Alternative Process Given Market Conditions and its Belief in its Ability to Build on Recent Operational Success Company Concludes Strategic Alternative Process Given Marke...
InteliSwab® COVID-19 Rapid Test Validated to Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants
BETHLEHEM, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced t...